Alert detail

LCD L40222: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — Noridian

Policy ID: LCD-L40222Specialty: Clinical LaboratoryAdded: 8/27/2026Effective: October 12, 2026lcd
High

What changed

Noridian finalizes non-NGS cancer panel test coverage rules eff. 10/12/2026

Who’s affected: Clinical Laboratory billing teams · Effective: October 12, 2026

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 10 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Clinical Laboratory audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Clinical Laboratory— the week’s changes and deadlines, delivered to your inbox. No account required.